HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Фаза 2
Идёт, набор закрыт
NCT04619004
| Заболевание | Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Daiichi Sankyo |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 277 участн. |
|---|
| Вмешательство | Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration) |
|---|
| Дата начала | 2.02.2021 |
|---|
| Дата завершения | 21.11.2022 |
|---|
| Публикация результатов | 2.04.2024 |
|---|
Кратко
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months · Participants
| Patritumab Deruxtecan 5.6 mg/kg | 64 Participants |
|---|
| Patritumab Deruxtecan Up-Titration | 8 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.